Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes
- 435 Downloads
Chronic inflammation contributes to insulin resistance and type 2 diabetes mellitus (T2DM). We investigated whether treatment with salsalate, an anti-inflammatory medication, improves glycemia in a group of newly diagnosed drug-naïve patients with T2DM. The study was a randomized, double-blind, placebo-controlled trial. Diagnosis of T2DM was made within 2 months of enrollment, and participants had not received any anti-glycemic agent. Sixty adults were randomized to receive salsalate (3 g/day) or placebo for 12 weeks. Fasting plasma glucose and insulin, glucose 2 h after 75 g oral glucose, HbA1C, lipid profile, HOMA-IR, and HOMA-B were determined before and after treatment. Salsalate reduced fasting glucose from 6.3 ± 0.2 mmol/l to 5.4 ± 0.2 mmol/l (P < 0.01) and TG from 1.9 ± 0.2 mmol/l to 1.5 ± 0.2 mmol/l (P < 0.03). Fasting insulin levels were increased in the salsalate group from 18.8 ± 1.6 to 21.6 ± 3.9, while they decreased in the placebo group. HbA1c rose in the placebo group from 6.2% ± 0.2 to 7.9% ± 1.1 mmol/mol, but decreased in the intervention group from 6.1% ± 0.5 to 5.6% ± 0.2 mmol/mol (P < 0.04 for between-group comparison). HOMA-IR did not change but HOMA-B increased ~1.7-fold (P = 0.06) in the salsalate group. The results show that salsalate is effective in improving glycemic control in newly diagnosed naïve patients with T2DM. The optimal duration of treatment with salsalate and sustainability of its effect requires further study (IRCT138709011465N1).
KeywordsSalsalate Type 2 diabetes Glycemic control
No potential conflicts of interest relevant to this article were reported. E.F. wrote the manuscript and researched data. A.A. reviewed/edited the manuscript. H.R. And P.A. reviewed/edited the manuscript. F.I-B. contributed to the discussion and reviewed/edited the manuscript. M.A. researched data and contributed to discussion. The authors thank Majid Abyar, Maryam Zare, Atsa Noruzi and all the staff of the Isfahan Endocrinology and Metabolism Research Center. The authors acknowledge Isfahan University of Medical Sciences for the financial support of this study as a dissertation for E.F.
Conflicts of interest
Nothing to declare.
- 2.zachary t. bloomgarden (2003) Inflammation and insulin resistance. Diabetes Care 26(6):1922–1926Google Scholar
- 11.Shoelson SE, Lee J, Yuan M (2003) Inflammation and the IKKβ/IκB/NF-κB axis in obesity and diet-induced insulin resistance. Int J Obes Relat Metab Disord 27(Suppl. 3):S49–S52Google Scholar
- 16.Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, Forbes J, de Courten B, Krakoff J (2009) The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomized double-blind placebo-controlled study. Diabetologia 52:385–393PubMedCrossRefGoogle Scholar
- 22.Anonymous (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:S62, 8 ppGoogle Scholar
- 23.Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE, for the TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team (2010) The effects of Salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152:346–357PubMedCrossRefGoogle Scholar
- 27.Haiyan Xu, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Hong Chen J (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Clin Invest 112:1821–1830Google Scholar